OpGen (NASDAQ:OPGN) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of OpGen (NASDAQ:OPGN) in a research note released on Friday. The brokerage issued a sell rating on the medical research company’s stock.

OpGen Trading Up 8.2 %

OPGN opened at $1.81 on Friday. OpGen has a one year low of $1.49 and a one year high of $9.90. The business’s 50-day simple moving average is $1.89 and its 200-day simple moving average is $2.81.

OpGen (NASDAQ:OPGN) last announced its quarterly earnings results on Monday, August 19th. The medical research company reported ($1.18) EPS for the quarter. The business had revenue of $0.03 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in OpGen stock. Chase Investment Counsel Corp purchased a new stake in OpGen, Inc. (NASDAQ:OPGN) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 331,890 shares of the medical research company’s stock, valued at approximately $230,000. Chase Investment Counsel Corp owned 2.63% of OpGen as of its most recent SEC filing. Hedge funds and other institutional investors own 2.68% of the company’s stock.

About OpGen

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.